A.R.T. Advisors’s Cardiff Oncology CRDF Stock Holding History

A.R.T. Advisors’s Portfolio CRDF Stock Details CRDF Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-18,378	Closed	-$28K	–	1399
2019 Q3	$28K	Buy	18,378 +1,781	+11%	+$3.47K	﹤0.01%	1356
2019 Q2	$41K	Sell	16,597 -2,082	-11%	-$6.68K	﹤0.01%	1259
2019 Q1	$70K	Buy	18,679 +10,381	+125%	+$37.1K	﹤0.01%	1200
2018 Q4	$26K	Sell	8,298 -13,073	-61%	-$59.6K	﹤0.01%	1242
2018 Q3	$104K	Buy	+21,371	New	+$101K	﹤0.01%	1271
2015 Q3	–	Sell	-823	Closed	-$601K	–	1388
2015 Q2	$601K	Buy	+823	New	+$584K	0.02%	926

Other funds holding CRDF

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

LWA

LWS Wealth Advisors Basking Ridge, New Jersey $266M AUM 12.97% 1-Year Est. Return

Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

Elkhorn Partners Omaha, Nebraska $117M AUM 28.12% 1-Year Est. Return

PFS

Prospera Financial Services Dallas, Texas $6.89B AUM 37.41% 1-Year Est. Return

Wedbush Securities Los Angeles, California $3.88B AUM 32.38% 1-Year Est. Return

Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

A.R.T. Advisors's CRDF Position: Q4 2019 in Review

A.R.T. Advisors sold out of Cardiff Oncology (CRDF) in Q4 2019, closing a stake of 18,378 shares — an estimated $28K sold.

A.R.T. Advisors first reported a position in CRDF in Q2 2015 and held it in 6 quarters. The position peaked at $601K in Q2 2015. 19 funds tracked by Wall St. Rank hold CRDF as of Q4 2019.

A.R.T. Advisors reported no remaining Cardiff Oncology position as of Q4 2019 after selling out during the quarter.
A.R.T. Advisors sold 18,378 Cardiff Oncology shares in Q4 2019, an estimated $28K.
A.R.T. Advisors first reported a position in Cardiff Oncology in Q2 2015 and held it in 6 quarters.
A.R.T. Advisors's Cardiff Oncology position peaked at $601K in Q2 2015.
19 funds tracked by Wall St. Rank held Cardiff Oncology as of Q4 2019.

Based on A.R.T. Advisors's 13F filing for Q4 2019, filed 14 Feb 2020.